You just read:

Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis

News provided by

Regeneron Pharmaceuticals, Inc.

Sep 16, 2017, 02:15 ET